Saturday's attack is the biggest on Saudi oil infrastructure since Saddam Hussein's invasion of Kuwait in 1990.Energyread more
"Blaming Iran won't end disaster. Accepting our April '15 proposal to end war & begin talks may," Zarif said on Twitter.Energyread more
Oil prices are expected to jump as much as $10 per barrel after a coordinated drone strike hit Saudi Arabia's largest oil field, forcing the kingdom to cut its oil output in...Marketsread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
Trusii's hydrogen water machines were supposed to help users with their health problems, but customers claim the company is involved in a giant scam.Technologyread more
The decoupling of the world's two weightiest economies seems as inescapable as its extent and global impact remains incalculable.Politicsread more
BlackBerry has reinvented itself to become a leader in securing mobile communications and in embedded communications. Next year it plans to roll out new products. CEO John...Evolveread more
Trailers have become a cult phenomenon. Even short teasers that reveal little about the plot of the upcoming film are headline-worthy. Blogs and forums have become devoted...Entertainmentread more
Thanks to the performance of Beyond Meat, investors who focus on venture-backed tech IPOs have done well this year despite some notable disappointments.Technologyread more
Software company Intuit, maker of tax helper TurboTax, is in its eleventh year of stock gains and up 36% this year.Investingread more
CNBC did a deep dive through the most recent Wall Street research to find stocks with upside potential.Marketsread more
Fitbit has made its first-ever start-up investment, putting more than $6 million into an enterprise called Sano, which is developing a coin-sized patch that tracks blood sugar levels to help control diabetes.
Building blood-sugar tracking into a future device could dramatically increase the market for Fitbit devices since more than 100 million Americans are now living with diabetes or pre-diabetes, according to the Centers for Disease Control and Prevention. Fitbit has recently suffered declining sales: It sold 3.6 million devices in the quarter ended Sept. 30, down from 5.3 million a year earlier.
Apple is known to have a research team working on a noninvasive glucose reader, as CNBC first reported in April. The New York Times in December reported that the project was authorized by late Apple CEO Steve Jobs while embroiled in a personal battle with diabetes, and current CEO Tim Cook has been seen testing a personal glucose monitor.
The Apple Watch is Fitbit's most formidable competitor.
Fitbit CEO James Park confirmed the Sano deal this week to CNBC. The investment is part of a larger financing round that Sano expects to close in coming months.
"This fits into our strategy of looking beyond the device and thinking more about (health) solutions," said Park. "I think the complete solution comes in the form of having some monitoring solution that is coupled with a display, and a wearable that can give you the interventions at the right moment," he said.
Fitbit already has partnerships with wearable device makers Medtronic and Dexcom that involve integrating blood sugar data with its consumer hardware. Park declined to say whether a future version of Fitbit's wearable devices will include built-in glucose tracking.
Sano's approach isn't noninvasive like Apple's might be because it involves using tiny needles.
But Sano CEO Ashwin Pushpala said it's a less painful option than the current alternatives, which include Abbott's popular FreeStyle Libre, because its device doesn't penetrate as deeply into the skin. It's also a cheaper option that needs to be changed more regularly, he said.
Sano's device won't be ready to hit the market for about a year and is likely intended for people with either Type 1 or Type 2 diabetes, said Pushpala. It might also be used by those who are pre-diabetic, or simply curious about how food and exercise affect their blood sugar.
Biosensor experts are still debating whether noninvasive approaches for tracking glucose, as Apple is planning, will ever be sufficiently reliable and accurate.
Pharma giants like Johnson & Johnson have unsuccessfully tried to bring this "holy grail" to market.
Alphabet's Verily is also working on hardware and software diabetics. It is teaming with Dexcom to develop a continuous glucose monitor for people with Type 2 diabetes, and it has a joint venture with Sanofi also targeted to people with the disease. In 2014, its own research team unveiled a prototype for a blood-sugar tracking contact lens.